Pembrolizumab in Previously Untreated Chinese Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: KEYNOTE-042 China Extension Study

ZHOU Qing

doi:10.12019/j.issn.1671-5144.2021.04.003

ZHOU Qing. Pembrolizumab in Previously Untreated Chinese Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: KEYNOTE-042 China Extension Study[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 202-207. DOI: 10.12019/j.issn.1671-5144.2021.04.003

Citation:

ZHOU Qing. Pembrolizumab in Previously Untreated Chinese Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: KEYNOTE-042 China Extension Study[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 202-207. DOI: 10.12019/j.issn.1671-5144.2021.04.003

Citation:

ZHOU Qing. Pembrolizumab in Previously Untreated Chinese Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: KEYNOTE-042 China Extension Study[J]. Journal of Evidence-Based Medicine, 2021, 21(4): 202-207. DOI: 10.12019/j.issn.1671-5144.2021.04.003

Pembrolizumab in Previously Untreated Chinese Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: KEYNOTE-042 China Extension Study

ZHOU Qing

Graphical Abstract

Abstract

FullText(HTML)

References (6)

Pembrolizumab in Previously Untreated Chinese Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: KEYNOTE-042 China Extension Study

Catalog

Export File

Citation

Format

Content